Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Auxilium’s Peyronie’s Strategy: Start With Few Urologists, Broad Patient Population

This article was originally published in The Pink Sheet Daily

Executive Summary

Xiaflex is first drug approved for Peyronie’s disease; initial marketing will focus on physicians that already provide invasive treatment.

You may also be interested in...

Endo Makes A Play For Auxilium, But QLT Deal Gets In The Way

The Irish company made its interest for Auxilium public, but the takeover target is not ready to break its previous merger agreement with Canadian drugmaker QLT.

Xiaflex Sales Still Slow, But Other Indications In The Works

Auxilium’s Xiaflex sales still languish, but its older testosterone product continues to drive growth for the company.

Auxilium's Xiaflex Clears FDA With REMS To Educate Doctors On Safe Injection Techniques

REMS does not restrict type of physician who can administer the collagenase enzyme, which will launch in March.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts